Your browser doesn't support javascript.
The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada.
Bettinger, Julie A; Sadarangani, Manish; De Serres, Gaston; Valiquette, Louis; Vanderkooi, Otto G; Kellner, James D; Muller, Matthew P; Top, Karina A; Isenor, Jennifer E; McGeer, Allison; Marty, Kimberly.
  • Bettinger JA; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada jbettinger@bcchr.ubc.ca.
  • Sadarangani M; Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
  • De Serres G; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Valiquette L; Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Vanderkooi OG; CHU de Québec-Université Laval, Quebec, Québec, Canada.
  • Kellner JD; Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie-Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Muller MP; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada.
  • Top KA; Pediatrics, University of Calgary, Calgary, Alberta, Canada.
  • Isenor JE; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada.
  • McGeer A; Pediatrics, University of Calgary, Calgary, Alberta, Canada.
  • Marty K; Medicine, Unity Health Toronto, Toronto, Ontario, Canada.
BMJ Open ; 12(1): e051254, 2022 01 20.
Article in English | MEDLINE | ID: covidwho-1642869
ABSTRACT

INTRODUCTION:

COVID-19 vaccines require enhanced safety monitoring after emergency approval. The Canadian National Vaccine Safety Network monitors the safety of COVID-19 vaccines and provides enhanced monitoring for healthy, auto-immune, immunocompromised, pregnant and breastfeeding populations and allows for the detection of safety signals. METHODS AND

ANALYSIS:

Online participant reporting of health events in vaccinated and unvaccinated individuals 12 years of age and older is captured in three surveys 1 week after dose 1, 1 week after dose 2 and 7 months after dose 1. Medically attended events are followed up by telephone. The number, percentage, rate per 10 000 and incident rate ratios with 95% CIs are calculated by health event, vaccine type, sex and in 10-year age groups. ETHICS AND DISSEMINATION Each study site has Research Ethics Board approvals for the project (UBC Children's & Women's, CIUSSS de l'Estrie-CHUS, Health PEI, Conjoint Health Research Ethics Board, University of Calgary and Alberta Health Services, IWK Health, Unity Health Toronto and CHU de Québec-Université Laval Research Ethics Boards). Individuals are invited to participate in this active surveillance and electronic consent is given before proceeding to each survey. Weekly reports are shared with public health and posted on the study website. At least one peer-reviewed manuscript is produced.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Child / Female / Humans / Pregnancy Country/Region as subject: North America Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-051254

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Child / Female / Humans / Pregnancy Country/Region as subject: North America Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-051254